Triple immunotherapy cocktail tested in advanced cancers
NCT ID NCT04495257
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best dose. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APX005M (an experimental immune-boosting drug) combined with nivolumab and ipilimumab (two approved immunotherapy drugs)
- What this could lead to
- If this combination proves safe and effective, it could lead to a new treatment option for advanced melanoma and kidney cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 26 participants, focused on safety and dosing. The combination may cause severe side effects, and it is too soon to know if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new biologic drug shrink advanced melanoma tumors?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?